Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
NCT ID: NCT02906852
Last Updated: 2019-05-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
264 participants
OBSERVATIONAL
2016-08-01
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Concordance of Inivata Liquid Biopsy With Standard Tissue Biopsy
NCT03116633
LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer
NCT02511288
Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants
NCT00899028
Accelerating Lung Cancer Diagnosis Through Liquid Biopsy
NCT04863924
Pilot Study of High Risk Lung Cancer Screening
NCT03683940
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In addition there is data-collection of treatments received for non small cell lung cancer and the response to these treatments during the first 6 months post tissue and blood analysis, though no additional visits or procedures are required for the patient beyond the initial blood draw.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male and female patients aged 18 years and over diagnosed with stage IIIb/IV non-squamous NSCLC.
* Arms A and B: Patients intended to initiate first-line treatment according to standard guidelines. Note, a patient is eligible to receive sterotactic radiosurgery (no whole-brain radiotherapy). Arm C: Patients who are at a second-line treatment setting or greater may participate. Note, a patient may be included if they have metastatic brain lesions. Arms A, B, C: If enrolled in a treatment clinical trial, patients may also enroll in this study if all eligibility criteria are met.
* Arm A only: Patients intended to initiate first-line treatment according to standard guidelines who plan to have or have had a recent tumor tissue biopsy taken for molecular profiling as part of their standard of care.
* Patient must understand and be able, willing and likely to fully comply with all study procedures and restrictions.
Exclusion Criteria
* Patients who have any other prior metastatic or current second primary cancer (Arms A and B)
* Patient who has a severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vector Oncology
OTHER
Inivata
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ramaswamy Govindan, MD
Role: PRINCIPAL_INVESTIGATOR
Washington University School of Medicine
Edward Kim, MD
Role: PRINCIPAL_INVESTIGATOR
Atrium Health Levine Cancer Institute
Clive Morris, MD
Role: STUDY_DIRECTOR
Inivata
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Facey Medical Foundation
Mission Hills, California, United States
University of Colorado Cancer Center
Aurora, Colorado, United States
Eastern CT Hematology Oncology
Norwich, Connecticut, United States
Christiana Care Health Services Inc
Newark, Delaware, United States
Holy Cross Hospital
Fort Lauderdale, Florida, United States
Mid-Florida Hematology and Oncology Centers
Orange City, Florida, United States
Swedish Covenant Hospital
Chicago, Illinois, United States
Edward M Kaplan, MD & Associates
Skokie, Illinois, United States
Cotton O'Neil Clinical Research Center
Topeka, Kansas, United States
Norton Healthcare Inc
Louisville, Kentucky, United States
Christus Cancer Treatment Center
Shreveport, Louisiana, United States
Berkshire Hematology Oncology Services
Pittsfield, Massachusetts, United States
Henry Ford Allegiance Health
Jackson, Michigan, United States
Park Nicolett
Saint Louis Park, Minnesota, United States
Jackson Oncology Associates, PLLC
Jackson, Mississippi, United States
Boone Hospital Center
Columbia, Missouri, United States
Washington University (St. Louis)
St Louis, Missouri, United States
Nebraska Methodist Hospital
Omaha, Nebraska, United States
Northshore Hematology Oncology
East Setauket, New York, United States
Northern Westchester Hospital Association
Mount Kisco, New York, United States
East Carolina University
Greenville, North Carolina, United States
Levine Cancer Center
Mint Hill, North Carolina, United States
Pinehurst Medical Clinic
Pinehurst, North Carolina, United States
Trinity Cancer Center
Minot, North Dakota, United States
Providence Health and Services
Portland, Oregon, United States
Gettysburg Cancer Center
Gettysburg, Pennsylvania, United States
Carolina Blood and Cancer Care
Rock Hill, South Carolina, United States
The West Clinic
Germantown, Tennessee, United States
Tennessee Cancer Specialists
Knoxville, Tennessee, United States
Thomas Spann Clinic Oncology
Corpus Christi, Texas, United States
Hope Cancer Center of East Texas (Tyler Hem Onc)
Tyler, Texas, United States
Virginia Cancer Institute
Richmond, Virginia, United States
Providence Regional Medical Center
Everett, Washington, United States
University of Washington (Swedish General)
Seattle, Washington, United States
Northwest Medical Specialties
Tacoma, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INI001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.